Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0600

+16.5%

Nov 26 3:10 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: LT2011 who wrote (11381)	6/27/2012 1:35:16 PM
From: NTTG	2 Recommendations Read Replies (1) of 13111

Before we get to a discussion of possible market size the more pressing question will be who will be willing to step up and put $ on the table for the PIII trial? Frankly, I thought they had a shot at studying stage III/IV disease further, but clearly the company had to pull back to less aggressive, non nodal, slow progressing stage III disease; which will not be as interesting to potential corporate sponsors. The trial design and patients studied define what anyone can say if/when PV-10 becomes a promotable product in the US. I anticipate the comparator arm will do well in these less aggressive patients, not so sure now that PVCT will do better. As predicted long ago the company had to get mouse data before starting the PIIb MOA clinical trials; but these are less important now (the bystander effect in 'stable disease' is less interesting than in a patients who's disease burden and progression demand a higher level of concern, IMO). The next 6 months will be interesting for PVCT, final protocol is the next big hurdle they have to get right...so far, negotiating patient types for inclusion did not go so good.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next